Physician
Gastroenterology
Dr. Kuchikula R. Reddy, MD
|
|
Give Review
Dr. Kuchikula R. Reddy practices Gastroenterology. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Kuchikula Reddy is a published doctor and has 40 publications published. The lastest was: 'Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.' Kuchikula Reddy accepts all Medicare patients.
Publications
- Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status.
- Review article: safety and tolerability of direct-acting anti-viral agents in the new era of Hepatitis C therapy.
- Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent Hepatitis C infection.
- Safety and Efficacy of Ledipasvir-Sofosbuvir in African Americans with Hepatitis C Virus Infection: A Retrospective Analysis of Phase 3 Data.
- HCV Council - Critical Appraisal of Data: Recommendations for Clinical Practice in a Rapidly Evolving Therapeutic Landscape.
- Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic Hepatitis B patients in the US - the ENUMERATE study.
- Interferon-free Therapy for Genotype 1 Hepatitis C in Liver Transplant Recipients: Real World Experience from HCV-TARGET.
- Population-representative Incidence of Drug-induced Acute Liver Failure Based on an Analysis of an Integrated Healthcare System.
- Outcomes in pediatric Hepatitis C transplant recipients: Analysis of the UNOS database.
- Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset.
- 2-year outcomes in Initial survivors with Acute Liver failure: Results from a Prospective, Multicenter Study.
- Drug-Induced Liver Injury due to Cancer Chemotherapeutic Agents.
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis.
- Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
- HCV Therapy With Daclatasvir, PEG-IFN, and RBV After Boceprevir-Based Therapy Failure Post-Liver Transplantation in Hyper-IgM Syndrome.
- Reliability of causality assessment for drug, herbal and dietary supplement hepatoxicity in the Drug-Induced Liver Injury Network (DILIN).
- Liver Transplantation and cirrhotomimetic hepatocellular carcinoma: Classification and outcomes.
- Distinct Features in Natural History and Outcomes of Acute Hepatitis C.
- Chronic Hepatitis E Virus Infection: Challenges in Diagnosis and Recognition in the United States.
- End-stage renal Disease after liver transplantation in patients with pre-transplant chronic kidney Disease.
- Donor hemosiderosis does not affect liver function and regeneration in the setting of living donor liver transplantation.
- Relationship Between Characteristics of Medications and Drug-Induced Liver Disease Phenotype and Outcome.
- Acetaminophen-related hepatotoxicity.
- Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administration's Mini-Sentinel Distributed Database.
- NS5A inhibitor, daclatasvir , for the treatment of chronic Hepatitis C virus infection.
- Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.
- Underreporting of Liver Transplant Waitlist Removals Due to Death or Clinical Deterioration: Results at Four Major Centers.
- Treatment of chronic Hepatitis C with protease inhibitor-based therapy after liver transplantation.
- Hepatitis B and C in African Americans: Current Status and Continued Challenges.
- Factors that Predict Short-Term Intensive Care Unit Mortality in Patients with Cirrhosis.
- Sofosbuvir , a nucleotide polymerase inhibitor, for the treatment of chronic Hepatitis C virus infection.
- Chronic kidney Disease (CKD) after liver transplantation in HIV/HCV coinfected versus HIV/non-HCV infected recipients: Results from the NIH multi-site study.
- Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis.
- Review article: herbal and dietary supplement hepatotoxicity.
- Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies.
- Pruritus in chronic cholestatic liver Disease.
- Ribavirin: current role in the optimal clinical management of chronic Hepatitis C.
- Boceprevir plus peginterferon α-2b/ribavirin in chronic Hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
- Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance.
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- Liver Biopsy
Conditions Treated
- Abdominal Pain
- Anemia
- Benign Neoplasm of the Digestive System
- Biliary Atresia
- View All
Doctors Specialties
- Gastroenterology
- Transplant Hepatology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
East Tennessee State University -
Osmania Medcial College NTR UHS
Hospital
-
Hospital of the University of Pennsylvania -
Penn Presbyterian Medical Center
Drug Facts
| NPI NUMBER | 1992848519 | |
| NPPES Provider LastName | REDDY | |
| NPPES Provider FirstName | KUCHIKULA | |
| NPPES Provider ZIPCode | 191044206 | |
| NPPES Provider State | PA | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 223.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1992848519 |
| Last Name Of The Provider | REDDY |
| First Name Of The Provider | KUCHIKULA |
| View All |
Similar Doctors
|
|
Dr. Abhik Roy, MD |
|
|
Dr. Jan-Michael Klapproth, MD |
|
|
Dr. Daniel M. Quirk, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher S. Kleeman, MD |
|
|
Dr. Kaveh Sharzehi, MD |
|
|
Dr. Bhavik M. Bhandari, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bruce P. Gelman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard A. Gambescia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nuzhat Ahmad, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Marianne T. Ritchie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David A. Sass, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert Fisher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Larry M. Borowsky, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael C. Dimarino, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ranjeeta R. Bahirwani, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mitchell I. Conn, MD
This Doctor is OpenDoctor Recommended.
|